Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
COGT 
Cogent Biosciences Inc (COGT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/20/2025: COGT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $16.2
1 Year Target Price $16.2
| 5 | Strong Buy |
| 4 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -37.92% | Avg. Invested days 27 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/20/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 808.38M USD | Price to earnings Ratio - | 1Y Target Price 16.2 |
Price to earnings Ratio - | 1Y Target Price 16.2 | ||
Volume (30-day avg) 12 | Beta 0.23 | 52 Weeks Range 3.72 - 12.61 | Updated Date 06/30/2025 |
52 Weeks Range 3.72 - 12.61 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.97 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -47.45% | Return on Equity (TTM) -84.04% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 688545105 | Price to Sales(TTM) 1320.63 |
Enterprise Value 688545105 | Price to Sales(TTM) 1320.63 | ||
Enterprise Value to Revenue 925.41 | Enterprise Value to EBITDA -3.89 | Shares Outstanding 113856000 | Shares Floating 73603643 |
Shares Outstanding 113856000 | Shares Floating 73603643 | ||
Percent Insiders 0.16 | Percent Institutions 118.62 |
Analyst Ratings
Rating 4 | Target Price 16.2 | Buy 4 | Strong Buy 5 |
Buy 4 | Strong Buy 5 | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Cogent Biosciences Inc
Company Overview
History and Background
Cogent Biosciences, Inc. (COGT) is a biotechnology company focused on developing precision therapies for genetically defined diseases. Founded in 2014, the company has advanced its pipeline through clinical trials, focusing on kinase inhibitors for cancer and other diseases.
Core Business Areas
- Precision Oncology: Development of selective kinase inhibitors to target specific mutations driving cancer growth.
- Systemic Mastocytosis: Development of therapies for systemic mastocytosis, a rare hematologic disorder.
Leadership and Structure
The company is led by a management team with experience in biotechnology and pharmaceutical development. The organizational structure is typical of a clinical-stage biotech company, with departments focused on research, development, clinical operations, and commercial strategy.
Top Products and Market Share
Key Offerings
- Bezverimab: Bezverimab is being developed for the treatment of advanced systemic mastocytosis (ASM). It is Cogent's lead product. Being in a clinical trial, there is no revenue. Key competitors for Systemic Mastocytosis therapy are Blueprint Medicines (BLUP) with AYVAKIT and potentially other companies developing therapies in this area.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. Advances in genomics and precision medicine are driving innovation.
Positioning
Cogent Biosciences is positioned as a precision medicine company focused on developing targeted therapies for genetically defined diseases. Its competitive advantage lies in its selective kinase inhibitor platform.
Total Addressable Market (TAM)
The TAM for targeted cancer and rare disease therapies is substantial, estimated to be in the billions of dollars. Cogent is positioned to capture a portion of this market with its lead product candidate and pipeline.
Upturn SWOT Analysis
Strengths
- Targeted therapy approach
- Selective kinase inhibitor platform
- Strong preclinical and clinical data for Bezverimab
- Experienced management team
Weaknesses
- Limited commercial infrastructure
- Reliance on single lead product candidate
- High cash burn rate
- Susceptibility to clinical trial failures
Opportunities
- Expansion of pipeline into new indications
- Partnerships with larger pharmaceutical companies
- Accelerated regulatory approval pathways
- Increasing prevalence of genetically defined diseases
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Patent challenges
- Economic downturn affecting funding
Competitors and Market Share
Key Competitors
- BLUP
- ARRY
Competitive Landscape
Cogent competes with larger pharmaceutical companies and other biotech firms in the targeted therapy space. Its competitive advantage lies in its selective kinase inhibitor platform and focus on genetically defined diseases.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by the progression of clinical trials and expansion of the pipeline.
Future Projections: Future growth is dependent on the successful clinical development and regulatory approval of Bezverimab and other pipeline candidates. Analyst estimates project significant revenue growth if Bezverimab is approved.
Recent Initiatives: Recent initiatives include advancing Bezverimab into later-stage clinical trials and expanding the pipeline through internal research and development.
Summary
Cogent Biosciences is a clinical-stage biotech company with a promising lead product candidate, Bezverimab, targeting advanced systemic mastocytosis. The company's strength lies in its precision medicine approach and experienced management team. Key risks include clinical trial failures and competition. The company needs to carefully manage its cash burn rate and pursue strategic partnerships to maximize its growth potential.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry News
Disclaimers:
The information provided is for informational purposes only and does not constitute investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share figures are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cogent Biosciences Inc
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2018-03-29 | President, CEO & Director Mr. Andrew R. Robbins M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 205 | Website https://www.cogentbio.com |
Full time employees 205 | Website https://www.cogentbio.com | ||
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.